Zealand Pharma announces initiation of the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesity

Phase 3petrelintidePositive

AI Analysis

Summary

Zealand Pharma initiated the Phase 3 ZUPREME registrational program for petrelintide in patients with overweight or obesity. This marks advancement toward clinical confirmation of efficacy and safety in a late-stage development program.

Clinical Trial Data

Phase

Phase 3

Importance:7/10

Sentiment:

0.60

obesityoverweightPhase 3petrelintideZUPREME programregistrational

Related Companies

$ZEAL

Read the original article

Published by yahoo_finance on September 22, 2026 3:00 PM

Read Original